Start with the diagnosis and staging question
Diabetic retinopathy affects the retina, and treatment options can include injections, laser or surgery, depending on assessment. Before any MDT conversation is useful, the patient needs a clear answer to one question: is the diagnosis confirmed, and at what stage? That sounds basic, but it changes everything downstream. A records-based review cannot replace a direct retinal examination, and a remote opinion cannot confirm what a local ophthalmologist sees on the day.
For an overseas patient, the practical issue is whether the records already contain enough to describe the retina. Retinal images, OCT scans, fluorescein angiography reports and visual acuity measurements are the kind of documents a specialist would want to see. If those are missing, the first MDT question is not 'what treatment' but 'what still needs to be imaged or examined, and by whom'. The treating hospital decides what it needs; the patient's job is to ask what is missing before travelling.
A second diagnostic question is whether the diabetes history is complete enough to interpret the eye findings. Duration of diabetes, HbA1c trend, blood pressure, kidney function and current diabetes medicines all influence how a retina specialist reads the case. This is not about changing diabetes treatment from a distance. It is about giving the eye team the context they need to judge urgency and options.
What prior injections or laser actually mean for the plan
Previous treatment is not just background. It is a core part of the MDT question. If the patient has already had intravitreal injections, the discussion needs to establish which eye, how many, when, and what the response was. If laser photocoagulation has been done, the team needs to know the pattern, the date and whether the retina is stable, improving or worsening. Without that, any new recommendation is built on guesswork.
This is also where patients often discover a gap. They may remember 'I had laser' but not which type, or 'I had injections' but not the drug or the interval. The MDT cannot resolve that gap by assuming. The useful action is to request the actual procedure notes and follow-up imaging from the treating centre, then ask the China team whether those records are sufficient or whether something specific is missing.
A related question is what has already been tried and failed, or what was stopped and why. That is not a criticism of previous care. It is how a new team avoids repeating an approach that did not work, or avoids missing a complication. The patient should ask the MDT to state plainly what it considers already settled and what remains open.
Which specialties need to be in the room, and why
Diabetic retinopathy sits at the intersection of eye care and diabetes care. A genuine multidisciplinary discussion may involve ophthalmology, endocrinology and possibly nephrology or cardiology if blood pressure, kidney function or cardiovascular risk are relevant. The patient-facing question is not 'how many doctors' but 'which decisions require more than one specialty, and who is accountable for each'.
That distinction matters because an eye-only review may answer whether the retina needs treatment, but it may not answer whether the patient's overall diabetes control is safe for a procedure, or whether another condition needs attention first. Conversely, an endocrinology review alone cannot stage the retina. The MDT's value is in naming the interfaces: who decides on the eye intervention, who manages systemic risk, and who coordinates the timing.
For an overseas patient, there is a further question: does the hospital actually run a formal MDT for this case, or is the 'MDT' a series of separate appointments? Those are different things. A formal meeting may not be available for every patient, and no service can guarantee that a hospital will provide one. The honest question to ask is what format the hospital uses, who joins, and how the patient receives the combined conclusion.
The questions a records-based review can and cannot answer
A records-based opinion can help clarify whether the diagnosis and staging appear consistent, whether prior treatment is documented, and what additional information a specialist would want. It can also identify whether the case looks like one where multiple specialties should be involved. What it cannot do is confirm final eligibility, guarantee hospital acceptance, or replace the in-person retinal examination.
This is why the MDT discussion should answer a specific set of questions rather than produce a general impression. Does the record set support the stated diagnosis? Is the stage agreed? What prior treatments are confirmed? What is missing? Which specialty should lead? What alternatives exist, and what are their trade-offs? What does the patient need to confirm directly with the treating hospital?
Patients should also ask how uncertainty is handled. If the records are incomplete, does the team say so clearly, or does it fill the gap with an assumption? A useful MDT output names its own limits. That is more valuable than a confident answer that later turns out to be based on a missing scan.
What the patient must confirm with the treating hospital
Even a well-run MDT discussion does not transfer decision-making to the patient or to a coordination service. The treating hospital and its licensed clinicians decide suitability, treatment and scheduling. The patient's role is to confirm the practical points that no remote review can settle: what the hospital's own assessment requires, what its written plan includes, and what happens if the findings differ from the records.
A concrete way to do this is to ask for the hospital's written scope before committing. That means asking what is included in the quoted plan, what is excluded, and what remains undecided until the in-person examination. It also means asking who the patient should contact if the plan changes, and how follow-up is arranged after any procedure.
For diabetic retinopathy specifically, the patient should ask how the hospital handles the interaction between eye treatment and diabetes management. Will the eye team communicate with the diabetes team? Who adjusts diabetes medicines, and under what circumstances? These are clinical decisions for the treating clinicians, not for a coordination service, but the patient is entitled to know how the handover works.
How to prepare records and what to ask next
The most useful preparation is a clear, dated record set. Retinal images, OCT and angiography reports, visual acuity results, procedure notes for any injections or laser, and a summary of diabetes history and current medicines give the review something concrete to work with. A short cover note stating the patient's main question helps the team focus.
The next step is to ask the specific questions this article has raised, in writing, so the answers are documented. Does the hospital use a formal MDT for this case? Which specialties participate? What records are still missing? What does the written plan include and exclude? What must be confirmed in person? An initial enquiry is free and does not require buying a proxy consultation; it is simply a way to establish what information is needed and what the relevant next step is.
If symptoms are worsening, new or urgent, local care takes priority over an overseas enquiry. A remote discussion is not a substitute for timely assessment. For patients whose situation is stable and who are planning ahead, the goal is a well-documented question set that the treating team can answer directly.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.